Chief Scientific Officer (CSO) for OmniBio Dr. Charles Dinarello discusses Alpha-1 Antitrypsin (AAT) research and it's potential as a therapy for Type 1 diabetes. He is also a Professor of Medicine and Immunology at the University of Colorado Denver who has published over 700 original research articles on cytokines, particularly interleukin‐1 (IL‐1) and tumor necrosis factor, and is considered a "founding father" of cytokine biology. OmniBio Pharmaceutical, Inc. (OTCBB: OMBP) is a clinical‐stage bio pharmaceutical company that has licensed potential new therapies currently in development for an existing FDA approved drug -- Alpha‐1 Antitrypsin (AAT). OmniBio believes that the market opportunity for the use of AAT in treating Type 1 diabetes may exceed the current market. Connect with OmniBio: News: OmniBioPharma.com Facebook goo.gl LinkedIn: goo.gl Visit OmniBioPharma.com for SEC filings and additional information. Please refer to Safe Harbor statement at the end of the video. OmniBio, part of the WestMountain Asset Management portfolio, is evaluating AAT for the treatment of several diseases, including Type 1 diabetes, bone marrow transplantation complications (also known as graft versus host disease or GVHD), islet transplantation, HIV, influenza and certain bacterial disorders, including anthrax exposure.. Connect with WestMountain Asset Management: Facebook: WestMountainAM.com Twitter: WestMountainAM.com LinkedIn: WestMountainAM.com Blog: WestMountainAM.com

Dr. Charles Dinarello, Chief Scientific Officer of OmniBio, is a co-author of an article that is now available in the journal Blood, which is the premier journal of the American Society of Hematology. The paper describes the use of Alpha 1 antitrypsin (AAT) to treat mice with a lethal form of rejection of bone marrow transplantation. Mice survive the crisis with AAT treatment. OmniBio Pharmaceutical, Inc. (OTCBB: OMBP) is a clinical‐stage bio pharmaceutical company that has licensed potential new therapies currently in development for an existing FDA approved drug -- Alpha‐1 Antitrypsin (AAT). OmniBio believes that the market opportunity for the use of AAT in treating Type 1 diabetes may exceed the current market. Connect with OmniBio: News: OmniBioPharma.com Facebook goo.gl LinkedIn: goo.gl Visit OmniBioPharma.com for SEC filings and additional information. Please refer to Safe Harbor statement at the end of the video. OmniBio, part of the WestMountain Asset Management portfolio, is evaluating AAT for the treatment of several diseases, including Type 1 diabetes, bone marrow transplantation complications (also known as graft versus host disease or GVHD), islet transplantation, HIV, influenza and certain bacterial disorders, including anthrax exposure.. Connect with WestMountain Asset Management: Facebook: WestMountainAM.com Twitter: WestMountainAM.com LinkedIn: WestMountainAM.com Blog: WestMountainAM.com

beyond Profiles weekly look at the market. Connect with us www.beyondprofile.com twitter.com

Second FREE video in a NEW house flipping series! In this new FREE series by Armando Montelongo, he tells us the necessary tools needed in order to successfully flip a house in today's market. Connect with Armando! www.facebook.com www.twitter.com www.linkedin.com armandomontelongolive.tv

OmniBio CEO Dr. James Crapo talks about the important research taking place with Alpha-1 Antitrypsin (AAT). This safe and powerful molecule is being used in trials for type 1 diabetes and Graph vs. Host disease (GVH). OmniBio Pharmaceutical, Inc. (OTCBB: OMBP) is a clinical‐stage bio pharmaceutical company that has licensed potential new therapies currently in development for an existing FDA approved drug -- Alpha‐1 Antitrypsin (AAT). OmniBio believes that the market opportunity for the use of AAT in treating Type 1 diabetes may exceed the current market. Connect with OmniBio: News: OmniBioPharma.com Facebook goo.gl LinkedIn: goo.gl Visit OmniBioPharma.com for SEC filings and additional information. Please refer to Safe Harbor statement at the end of the video. OmniBio, part of the WestMountain Asset Management portfolio, is evaluating AAT for the treatment of several diseases, including Type 1 diabetes, bone marrow transplantation complications (also known as graft versus host disease or GVHD), islet transplantation, HIV, influenza and certain bacterial disorders, including anthrax exposure.. Connect with WestMountain Asset Management: Facebook: WestMountainAM.com Twitter: WestMountainAM.com LinkedIn: WestMountainAM.com Blog: WestMountainAM.com

TrillionAds - your networked online market. Connect the world through you and earn. An online market where anyone could advertises, sells or buys products and services. Quick overview on how everyone could earn with us. Absolutely free of cost opportunity.. Spend nothing more. Do nothing new. Just do it differently with us. No investment. No Inventory. No Sales or Purchase targets. Multiple earning possibilities -- when you buy or sell or even invite others. Every sale or purchase could earn up to 2410 Euro for you for next 24 months.. Earn up to 240 Euro per month for next 24 months, each time when your friends buy or sell. Earn with any product or service. Why not convert every money spend today into an earning stream, life long ? Register now and earn: www.trillionads.com